Arena Pharmaceuticals

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) had the FDA AdComm panel for Lorcaserin vote 5-9 against approval, owed largely to carcinogenicity concerns in light of the modest weight loss benefit, approval now pushed for at least three years, maybe even to 2015, Piper Jaffray reports. Piper Jaffray...

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) has a meeting scheduled September 16th for Lorcaserin's FDA Advisory Committee, and a positive committee vote is expected by Piper Jaffray. An intense focus should be on valve safety at the panel meeting, in which the guidelines should state that the...

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) has had its price target lowered to $5 (from $6) by Jefferies & Company, whic believes that the Lorcaserin heart valve safety analysis didn't meet the FDA cutoff, given the history of this class of weight loss drugs. Arena Pharmaceuticals will release...